AN2 Therapeutics, Inc. (ANTX) Stock Analysis and Metrics

AN2 Therapeutics

NASDAQ: ANTX

$4.93 ▲ +0.01 (+0.20%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap167.57 Mn

P/E-4.85

Div. Yield0.00

Add ratio to table…

About

AN2 Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company’s pipeline includes three Phase 2 studies expected to initiate in 2026, two preclinical candidates, and advanced research programs in oncology, bone disorders, and infectious diseases. The company operates in the biotechnology industry, targeting hematologic diseases, infectious diseases, and oncology.

AN2 Therapeutics generates revenue primarily through licensing agreements, milestone payments, and royalties from partners, as well as grant funding for its global health programs. The company has entered into agreements with Anacor Pharmaceuticals and Brii Biosciences that provide upfront payments, potential milestone payments contingent on development and commercial achievements, and tiered royalties on net sales of licensed products. Additionally, support from organizations such as the Adjuvant Global Health Technology Fund and government grants funds research activities for diseases like melioidosis and tuberculosis.

The company operates through the following segments: Hematologic Diseases, Infectious Diseases, and Oncology.

• Hematologic Diseases: This segment focuses on developing oral epetraborole for polycythemia vera, a blood cancer characterized by overproduction of red blood cells, with a Phase 2 trial planned for initiation in 2026.

• Infectious Diseases: This segment advances epetraborole for Mycobacterium abscessus complex lung disease and AN2-502998 for Chagas disease, alongside global health programs targeting melioidosis and tuberculosis through nondilutive funding.

• Oncology: This segment pursues preclinical programs targeting PI3Kα and ENPP1 to develop selective inhibitors aimed at overcoming limitations of existing therapies and enhancing immune mediated tumor clearance.

AN2 Therapeutics positions itself as an innovative player in the niche of boron based small molecule therapeutics, competing with larger biopharmaceutical firms that pursue similar disease areas but often rely on different chemical modalities. Its competitive advantage lies in the proprietary boron chemistry platform, which enables distinct target engagement and may improve safety profiles relative to existing treatments. While facing competition from established companies with approved therapies for polycythemia vera, Mycobacterium abscessus, and Chagas disease, the company’s focus on unmet medical needs and potential for first in class oral agents differentiates its approach.

As a prerevenue clinical stage company, AN2 Therapeutics does not yet serve commercial customers; its future customers are expected to include patients with polycythemia vera, Mycobacterium abscessus lung disease, and Chagas disease, as well as healthcare providers and hospitals that would prescribe its approved therapies. In the near term, the company collaborates with partners such as Anacor Pharmaceuticals, Brii Biosciences, Adjuvant Global Health Technology Fund, the University of Georgia Research Foundation, and Oregon Health and Sciences University to advance its research and development programs.

Investment Thesis

▲ Bull case

AN2 Therapeutics is positioned to unlock substantial near-term value inflection points through the advancement of three distinct Phase 2 programs in 2026, which the market may be underestimating given the company's current valuation relative to its pipeline breadth and clinical progress. The initiation of the Phase 2 polycythemia vera trial with epetraborole in Q3 2026, supported by robust preclinical and clinical data showing dose-dependent hematocrit reduction and favorable tolerability, addresses a clear unmet need in a disease affecting approximately 155,000 U.S. patients where current therapies rely on burdensome phlebotomy or injectables with long-term safety concerns. This oral, once-daily approach offers differentiated advantages in patient convenience and long-term adherence, potentially capturing significant market share if efficacy and safety profiles hold, with data readouts expected as early as Q4 2026 that could serve as a near-term catalyst for re-rating. Concurrently, the investigator-initiated Phase 2 trial in M. abscessus lung disease, now with FDA IND clearance and led by a leading expert at OHSU, targets a serious infection with no FDA-approved therapies and limited treatment options, affecting an estimated 12,000 to 22,500 U.S. patients based on 10–15% of the 120,000–150,000 NTM lung disease population; success here could establish epetraborole as a backbone agent in multidrug regimens, with topline data anticipated in late 2027 representing a medium-term value driver. Furthermore, the positive preclinical results from AN2-502998 in Chagas disease, demonstrating parasite elimination in NHPs after one month of treatment and an excellent safety profile in the FIH study, support the planned Phase 2 proof-of-concept launch later this year in a disease affecting over 300,000 people in the U.S. and approximately 10 million globally, where no FDA-approved therapies exist for adults and the commercial opportunity is framed as multi-billion-dollar due to parallels with the hepatitis C market transformation. The company’s boron chemistry platform enables structural novelty across these diverse indications, reducing competitive overlap and enhancing IP defensibility, while the recent $40 million private placement—priced to meet Nasdaq minimum price requirements and supported by existing and new institutional investors including Coastlands, Commodore, and Vivo Capital—strengthens the balance sheet to $81.8 million in stockholders’ equity as of Q1 2026, funding operations through 2029 and de-risking near-term execution. Management’s emphasis on advancing three Phase 2 programs this year, coupled with the platform’s versatility in oncology and infectious diseases, suggests multiple shots on goal that could yield outsized returns if even one program succeeds, particularly given the low current enterprise value relative to the potential peak sales of a single approved asset in these underserved markets.

AN2 Therapeutics is positioned to unlock substantial near-term value inflection points through the advancement of three distinct Phase 2 programs in 2026, which the market may be underestimating given the company's current valuation relative to its pipeline breadth and clinical progress. The initiation of the Phase 2 polycythemia vera trial with epetraborole in Q3 2026, supported by robust preclinical and clinical data showing dose-dependent hematocrit reduction and favorable tolerability, addresses a clear unmet need in a disease affecting approximately 155,000 U.S. patients where current therapies rely on burdensome phlebotomy or injectables with long-term safety concerns. This oral, once-daily approach offers differentiated advantages in patient convenience and long-term adherence, potentially capturing significant market share if efficacy and safety profiles hold, with data readouts expected as early as Q4 2026 that could serve as a near-term catalyst for re-rating. Concurrently, the investigator-initiated Phase 2 trial in M. abscessus lung disease, now with FDA IND clearance and led by a leading expert at OHSU, targets a serious infection with no FDA-approved therapies and limited treatment options, affecting an estimated 12,000 to 22,500 U.S. patients based on 10–15% of the 120,000–150,000 NTM lung disease population; success here could establish epetraborole as a backbone agent in multidrug regimens, with topline data anticipated in late 2027 representing a medium-term value driver. Furthermore, the positive preclinical results from AN2-502998 in Chagas disease, demonstrating parasite elimination in NHPs after one month of treatment and an excellent safety profile in the FIH study, support the planned Phase 2 proof-of-concept launch later this year in a disease affecting over 300,000 people in the U.S. and approximately 10 million globally, where no FDA-approved therapies exist for adults and the commercial opportunity is framed as multi-billion-dollar due to parallels with the hepatitis C market transformation. The company’s boron chemistry platform enables structural novelty across these diverse indications, reducing competitive overlap and enhancing IP defensibility, while the recent $40 million private placement—priced to meet Nasdaq minimum price requirements and supported by existing and new institutional investors including Coastlands, Commodore, and Vivo Capital—strengthens the balance sheet to $81.8 million in stockholders’ equity as of Q1 2026, funding operations through 2029 and de-risking near-term execution. Management’s emphasis on advancing three Phase 2 programs this year, coupled with the platform’s versatility in oncology and infectious diseases, suggests multiple shots on goal that could yield outsized returns if even one program succeeds, particularly given the low current enterprise value relative to the potential peak sales of a single approved asset in these underserved markets.

▼ Bear case

AN2 Therapeutics faces significant clinical and execution risks that the market may be overlooking, particularly the inherent uncertainty in translating preclinical and early clinical data across disparate disease areas, despite the company’s emphasis on the boron chemistry platform’s versatility. While epetraborole has shown hematocrit reduction in healthy volunteers and non-PV patients, there is no guarantee this mechanism will translate to efficacy and safety in polycythemia vera patients, a point explicitly acknowledged in the company’s forward-looking statements regarding the risk that observations in non-PV trials will not hold in the target population, and the PV indication represents a shift from the drug’s original infectious disease focus, raising questions about target specificity and off-target effects in a malignant hematopoietic context where long-term dosing safety remains unproven. Similarly, the leap from preclinical NHP data to human efficacy in Chagas disease with AN2-502998 is uncertain, despite promising parasite elimination in macaques, as the company itself notes the risk that results from preclinical models may not predict safety and efficacy in humans, and the FIH study only assessed safety in healthy volunteers over 10 days, providing no insight into long-term tolerability or efficacy in infected individuals, which is critical for a curative claim in a chronic disease where treatment duration and adherence are paramount. The M. abscessus investigator-initiated trial, while supported by IND clearance and expert leadership, introduces additional variability due to reliance on third-party investigators and institutions for trial conduct, with acknowledged risks including limited control over execution, site activation and retention, patient enrollment pace, and data quality—factors that could delay or undermine the topline data readout expected in late 2027, especially given the complexity of enrolling treatment-naïve patients with a difficult-to-diagnose infection in a multicenter setting. Financially, although the $40 million private placement bolsters the balance sheet, the company reported a net loss of $10.0 million in Q1 2026 and continues to burn cash, with operating expenses of $10.6 million in the quarter, and while the cash runway is stated to extend into 2029, this assumes no setbacks in clinical development that could necessitate additional, dilutive financing sooner than anticipated, particularly if any of the three Phase 2 programs encounter delays or unfavorable results requiring trial redesign or extension. Furthermore, the company’s reliance on investigator-initiated trials for key programs like M. abscessus reduces its ability to control timelines and outcomes, and the absence of recent earnings call transcripts limits transparency into management’s discussion of these risks, potentially masking evasiveness or uncertainty during Q&A that would otherwise surface in a formal setting. The broad pipeline across hematologic, infectious, and oncology indications, while diversifying risk, also spreads managerial and financial resources thin, increasing the chance that none of the programs receive sufficient focus to succeed, and the platform’s novelty, while a potential advantage, may face skepticism from regulators and clinicians unfamiliar with boron-based mechanisms, complicating approval and adoption paths even if clinical data are positive.

AN2 Therapeutics faces significant clinical and execution risks that the market may be overlooking, particularly the inherent uncertainty in translating preclinical and early clinical data across disparate disease areas, despite the company’s emphasis on the boron chemistry platform’s versatility. While epetraborole has shown hematocrit reduction in healthy volunteers and non-PV patients, there is no guarantee this mechanism will translate to efficacy and safety in polycythemia vera patients, a point explicitly acknowledged in the company’s forward-looking statements regarding the risk that observations in non-PV trials will not hold in the target population, and the PV indication represents a shift from the drug’s original infectious disease focus, raising questions about target specificity and off-target effects in a malignant hematopoietic context where long-term dosing safety remains unproven. Similarly, the leap from preclinical NHP data to human efficacy in Chagas disease with AN2-502998 is uncertain, despite promising parasite elimination in macaques, as the company itself notes the risk that results from preclinical models may not predict safety and efficacy in humans, and the FIH study only assessed safety in healthy volunteers over 10 days, providing no insight into long-term tolerability or efficacy in infected individuals, which is critical for a curative claim in a chronic disease where treatment duration and adherence are paramount. The M. abscessus investigator-initiated trial, while supported by IND clearance and expert leadership, introduces additional variability due to reliance on third-party investigators and institutions for trial conduct, with acknowledged risks including limited control over execution, site activation and retention, patient enrollment pace, and data quality—factors that could delay or undermine the topline data readout expected in late 2027, especially given the complexity of enrolling treatment-naïve patients with a difficult-to-diagnose infection in a multicenter setting. Financially, although the $40 million private placement bolsters the balance sheet, the company reported a net loss of $10.0 million in Q1 2026 and continues to burn cash, with operating expenses of $10.6 million in the quarter, and while the cash runway is stated to extend into 2029, this assumes no setbacks in clinical development that could necessitate additional, dilutive financing sooner than anticipated, particularly if any of the three Phase 2 programs encounter delays or unfavorable results requiring trial redesign or extension. Furthermore, the company’s reliance on investigator-initiated trials for key programs like M. abscessus reduces its ability to control timelines and outcomes, and the absence of recent earnings call transcripts limits transparency into management’s discussion of these risks, potentially masking evasiveness or uncertainty during Q&A that would otherwise surface in a formal setting. The broad pipeline across hematologic, infectious, and oncology indications, while diversifying risk, also spreads managerial and financial resources thin, increasing the chance that none of the programs receive sufficient focus to succeed, and the platform’s novelty, while a potential advantage, may face skepticism from regulators and clinicians unfamiliar with boron-based mechanisms, complicating approval and adoption paths even if clinical data are positive.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,785.72 Bn	-32.10 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,895.57 Bn	0.00 Bn	56,599.40	0.11 Bn
3	ONC	BeOne Medicines Ltd.	471.35 Bn	0.00 Bn	82.13	0.96 Bn
4	NCNA	NuCana plc	279.75 Bn	0.00 Bn	-	-
5	VRTX	Vertex Pharmaceuticals Inc / Ma	120.24 Bn	0.00 Bn	9.84	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.80 Bn	0.00 Bn	4.54	1.99 Bn
7	BLTE	Belite Bio, Inc	62.51 Bn	367.72 Bn	-	-
8	ARGX	Argenx Se	57.38 Bn	0.00 Bn	12.31	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password